Qais Abualassal1 
,
Zead Abudayeh1,
Manal Al-Najdawi1,
Samer H Hussein-Al-Ali2
For correspondence:- Qais Abualassal Email: qais.abualassal@iu.edu.jo Tel:+62790906530
Accepted: 6 April 2024 Published: 30 April 2024
Citation: Abualassal Q, Abudayeh Z, Al-Najdawi M, Hussein-Al-Ali SH. Glycan synthesis: An update. Trop J Pharm Res 2024; 23(4):783-794 doi: 10.4314/tjpr.v23i4.15
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Carbohydrate synthesis presents several challenges due to the intricate nature of molecules and their complex structures. Since certain pathogens are difficult to culture in the laboratory under some circumstances, and the isolation of glycans in pure structural forms is an arduous undertaking, the medicinal chemistry approach offers a fascinating and attractive option. The efforts being made to develop an automated system for oligosaccharide synthesis are expected to produce immense effects and revolutionize the understanding of the role of carbohydrates in biological systems. Glycovaccines aid in saving millions of lives around the world annually by protecting children and adults from bacterial infections. These vaccines further expand the therapeutic armamentarium against several microbial infectious diseases. This review highlights the different clinical applications of glycan and the progress made in their synthetic process.
Fulltext in PDF